title: Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.
authors.forename: Sengwee
authors.initials: S
authors.lastname: Toh
authors.forename: Meghan A
authors.initials: MA
authors.lastname: Baker
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Brown
authors.forename: Cynthia
authors.initials: C
authors.lastname: Kornegay
authors.forename: Richard
authors.initials: R
authors.lastname: Platt
mesh_terms: D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects*; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D018571:Sentinel Surveillance; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline